FDA has designated Editas Medicine's EDIT-301 candidate as an orphan drug for beta-thalassemia. Preparations are underway for a Phase 1/2 EDIT-301 clinical trial of the drug, which is planned for the end of the year.
FDA has designated Editas Medicine's EDIT-301 candidate as an orphan drug for beta-thalassemia. Preparations are underway for a Phase 1/2 EDIT-301 clinical trial of the drug, which is planned for the end of the year. 
ir.editasmedicine.com
English (US) 